Döhner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–77.

Article  Google Scholar 

Siegel RL, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.

Article  Google Scholar 

National Cancer Institute, SEER Cancer Stat Facts: Acute Myeloid Leukemia (AML). Available at: https://seer.cancer.gov/statfacts/html/amyl.html/ Accessed 12/17/18.

Ofran Y, Tallman MS, Rowe JM. How I treat acute myeloid leukemia presenting with preexisting comorbidities. Blood. 2016;128(4):488–96.

Article  CAS  PubMed Central  Google Scholar 

Ohtake S, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood. 2011;117(8):2358–65.

Article  CAS  Google Scholar 

Hao Q, et al. Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review. PLoS ONE. 2022;17(12): e0278578.

Article  CAS  PubMed Central  Google Scholar 

Haematologic Malignancy Research Network (HMRN). http://www.hmrn.org/factsheets#acute_myeloid_leukaemia

Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487–94.

Article  Google Scholar 

Ma TT, et al. Development and validation of a prognostic model for adult patients with acute myeloid leukaemia. EBioMedicine. 2020;62: 103126.

Article  CAS  PubMed Central  Google Scholar 

Sasaki K, et al. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol. 2022;97(7):865–76.

Article  CAS  Google Scholar 

Sasaki K, et al. De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021;127(12):2049–61.

Article  Google Scholar 

Kantarjian H, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):41.

Article  PubMed  PubMed Central  Google Scholar 

Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12):1916–24.

Article  PubMed Central  Google Scholar 

Appelbaum FR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481–5.

Article  CAS  PubMed Central  Google Scholar 

Röllig C, et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood. 2010;116(6):971–8.

Article  Google Scholar 

Lindsley RC, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367–76.

Article  CAS  PubMed Central  Google Scholar 

Prassek VV, et al. Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. Haematologica. 2018;103(11):1853–61.

Article  CAS  PubMed Central  Google Scholar 

Shimony S, et al. FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years. Blood Adv. 2023;7(18):5354–8.

Article  CAS  PubMed Central  Google Scholar 

Itzykson R, et al. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood. 2021;138(7):507–19.

Article  CAS  Google Scholar 

Sasaki K, et al. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2022;97(1):68–78.

Article  CAS  Google Scholar 

Klepin HD, Estey E, Kadia T. More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate. Am Soc Clin Oncol Educ Book. 2019;39:421–32.

Article  Google Scholar 

Datta SS, et al. How do clinicians rate patient’s performance status using the ECOG performance scale? A mixed-methods exploration of variability in decision-making in oncology. Ecancermedicalscience. 2019;13:913.

Article  PubMed Central  Google Scholar 

Ferrara F, et al. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia. 2013;27:997.

Article  CAS  Google Scholar 

Palmieri R, et al. Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm. J Clin Oncol. 2020;38(35):4163–74.

Article  CAS  PubMed Central  Google Scholar 

Ritchie EK, et al. Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101. Blood Adv. 2022;6(12):3812–20.

Article  CAS  PubMed Central  Google Scholar 

Min GJ, et al. Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML. Blood. 2022;139(11):1646–58.

Article  CAS  Google Scholar 

Senjo H, et al. A novel nutritional index “simplified CONUT” and the disease risk index independently stratify prognosis of elderly patients with acute myeloid leukemia. Sci Rep. 2020;10(1):19400.

Article  CAS  PubMed Central  Google Scholar 

Extermann M, et al. Treating acute myelogenous leukemia in patients aged 70 and above: Recommendations from the International Society of Geriatric Oncology (SIOG). J Geriatr Oncol, 2023;101626.

Löwenberg B, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235–48.

Article  Google Scholar 

Lancet JE, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018;36(26):2684–92.

Article  CAS  PubMed Central  Google Scholar 

Cortes JE, et al. Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial. J Hematol Oncol. 2022;15(1):155.

Article  CAS  PubMed Central  Google Scholar 

DiNardo CD, et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol. 2022;97(8):1035–43.

Article  CAS  Google Scholar 

Halpern AB, et al. Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia. 2018;32(11):2352–62.

Article  CAS  PubMed Central  Google Scholar 

Stone RM, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017;377(5):454–64.

Article  CAS  PubMed Central  Google Scholar 

Döhner H, et al. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. Blood Adv. 2022;6(18):5345–55.

Article  PubMed Central  Google Scholar 

Sierra J, et al. Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, FLT3-Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for 7+3 or 5+2 Chemotherapy. Blood. 2020;136(Supplement 1):23–4.

Article  Google Scholar 

Short NJ, Nguyen D, Ravandi F. Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors. Blood Cancer J. 2023;13(1):142.

Article  PubMed Central  Google Scholar 

Erba HP, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10388):1571–83.

Article  CAS  Google Scholar 

Grimwade D, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1312–20.